<DOC>
	<DOCNO>NCT01256073</DOCNO>
	<brief_summary>The trial multi-centre , open-label , safety tolerability extension trial IPH2101-101 ( previously NN1975-1733 ) first human dose trial complete large subject pool optimal dose level . The trial conduct elderly Acute Myeloid Leukemia ( AML ) patient age 60 year , complete remission , eligible allogeneic stem-cell transplantation . The dose give individual patient patient receive single dose trial IPH2101-101 1 mg/kg 2 mg/kg 12 patient additional cohort .</brief_summary>
	<brief_title>A Safety Tolerability Extension Trial Assessing Repeated Dosing Anti-KIR ( 1-7F9 ) Human Monoclonal Antibody Patients With Acute Myeloid Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity ( Trialrelated activity procedure would perform normal management subject ) 2 . Acute myeloid leukaemia ( AML ) accord WHO Criteria 3 . Morphological complete remission ( CR ) define accord NCI criterion , CRi incomplete platelet count recovery 1 2 cycle induction chemotherapy , least 1 , maximally 6 cycle consolidation chemotherapy : Absolute neutrophile count &gt; 1x 109/L Platelets &gt; 80x109/L Independency blood transfusion Less 5 % blast bonemarrow No Auer rods No symptoms disease 4 . Life expectancy &gt; 4 month judge Investigator 5 . The patient &gt; = 60 year age &lt; = 80 year age 6 . The patient complete participation IPH2101101 ( previously NN19751733 ) trial acceptable safety profile , judge Investigator screen additional cohort 7 . Time since last dose chemotherapy least 30 day 60 day patient participate IPH2101101 trial 8 . Recovery acute toxicity previous antileukaemic therapy 9 . KIRexpression patient NKcells ( ability bind AntiKIR ( 17F9 ) ) patient participate IPH2101101 trial 10 . ECOG performance status 0 , 1 2 11 . No major organ dysfunction judge Investigator 12 . The patient must follow clinical laboratory value : Serum creatinine &lt; = 2 md/dL Total bilirubin &lt; = 1.5 x upper limit normal Asparatate aminotransferase ( AST ) &lt; 3x upper limit normal 1 . Known suspect allergy trial product relate product 2 . Previous participation trial 3 . AML classify FAB M3 ( APL , acute promyelocytic leukaemia ) good prognosis AML i.e . ( 8 ; 21 ) ( q22 ; q22 ) inv ( 16 ) ( p13q22 ) ( 16 ; 16 ) ( p13 ; q22 ) molecular equivalent 4 . Eligibility allogeneic haematopoietic transplantation 5 . The patient currently receive , within last 4 week receive investigational antileukemic treatment cytokine treatment , except AntiKIR ( 17F9 ) 6 . The patient receive GCSF treatment within last 30 day prior screen 7 . Systemic steroid treatment within last 4 week prior screen 8 . Patient active autoimmune disease 9 . Diagnosis monoclonal gammopathy 10 . Patient active infectious disease 11 . Previous leukaemic CNS involvement 12 . Cardiac failure ( New York Heart Association [ NYHA ] grade IIIIV ) 13 . Left ventricular ejection fraction ( LVEF ) less 45 % normal evaluate ultrasound isotopic evaluation 14 . Severe neurological/psychiatric disorder 15 . HIV chronic hepatitis infection 16 . Clinical evidence active second malignancy 17 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 18 . Any new medical condition opinion Investigator disqualify patient inclusion</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>